5.9 C
New York
Friday, March 29, 2024

Stifel Terminates Coverage On Oncolytics Biotech Due To Reallocation Of Resources

Courtesy of Benzinga.

Related ONCY
US Stock Futures Up Ahead Of Existing-Home Sales Data
US Stock Futures Up Ahead Of Auto Sales, Construction Spending Data

In a report published Monday, Stifel analyst Brian Klein terminated coverage on Oncolytics Biotech (NASDAQ: ONCY).

In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be used as an indicator for the company going forward.”

Oncolytics Biotech closed on Friday at $0.42.

Latest Ratings for ONCY

Date Firm Action From To
Sep 2013 Needham Initiates Coverage on Buy
Mar 2013 Piper Jaffray Initiates Coverage on Overweight
Dec 2012 Bloom Burton & Co. Downgrades Buy Hold

View More Analyst Ratings for ONCY
View the Latest Analyst Ratings

Posted-In: Brian Klein StifelAnalyst Color Termination Analyst Ratings

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,449FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x